Latest

MaRCU: Investigating RNA mutations and functions in cancer pathways.

2017/12

p53 Workshop in Japan

DSCF3878-1-2The p53 Workshop in Japan took place during the ConBio2017 in Kobe and was co-organised by MaRCU and Rieko Ohki from the National Cancer Center Japan. We are very thankful to ConBio2017 and our invited speakers/dear friends: Sir David Lane (A*STAR), Masanobu Oshima (Kanazawa U) and Kanaga Sabapathy (National Cancer Center Singapore). It was a splendid workshop!

Click here for more details.

2017/08

Internal Ribosome Entry Site (IRES) discovered in the mRNA of mammalian Target Of Rapamycin (mTOR)

RNAjournal_logo_standaloneThe mRNA Metabolism group (Romão lab), together with MaRCU and Locker lab (UK), describe a new IRES (Internal Ribosome Entry Site) in the 5’UTR of mTOR mRNA that is required to resume cell-cycle progression following periods of cell starvation and global translational repression. Click here to learn more.

2017/08

実験医学8月号に私たちのレビュー論文: p53 mRNAおよびp53アイソフォームの新たな機能

EM1709_表紙明朝2

 

 

 

実験医学はこちらから注文できます.

 

 

2016/10

Mutant p53 functions depend on truncated isoforms

badgef1000

embor-logo

Wild‐type p53 functions as a tumour suppressor while mutant p53 functions as an oncogene. In this new study we propose that this switch depends on Δ160p53, the most conserved isoform of p53, which is overexpressed in p53 mutant cells.

Here is a video where Marco explains the importance of the findings:

Check out the original article at EMBO reports to learn more about:

  • Cells carrying p53 mutations overexpress shorter p53 isoforms.

  • The Δ160p53 isoform possesses pro‐oncogenic potential similar to mutant p53.

  • “Gain‐of‐function” cancer phenotypes induced by mutant p53 depend on the expression of short p53 isoforms.